Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis
Open Access
- 8 May 2009
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 219 (1) , 16-24
- https://doi.org/10.1002/path.2574
Abstract
Approximately 8% of breast cancers show increased copy numbers of chromosome 17 centromere (CEP17) by fluorescence in situ hybridization (FISH) (ie average CEP17 >3.0 per nucleus). Currently, this pattern is believed to represent polysomy of chromosome 17. HER2‐amplified cancers have been shown to harbour complex patterns of genetic aberrations of chromosome 17, in particular involving its long arm. We hypothesized that aberrant copy numbers of CEP17 in FISH assays may not necessarily represent true chromosome 17 polysomy. Eighteen randomly selected CEP17 polysomic cases and a control group of ten CEP17 disomic cases, as defined by dual‐colour FISH, were studied by microarray‐based comparative genomic hybridization (aCGH), which was performed on microdissected samples using a 32K tiling‐path bacterial artificial chromosome microarray platform. Additional FISH probes were employed for SMS (17p11.2) and RARA (17q21.2) genes, as references for chromosome 17 copy number. Microarray‐based comparative genomic hybridization revealed that 11 out of the 18 polysomic cases harboured gains of 17q with involvement of the centromere, one displayed 17q gain sparing the centromeric region, and only one could be defined as polysomic. The remaining five cases displayed amplification of the centromeric region. Among these, one case, showing score 2+ by immunohistochemistry and 8.5 HER2 mean copy number, was classified as not amplified by HER2/CEP17 ratio and as amplified by HER2/SMS ratio. Our results suggest that true chromosome 17 polysomy is likely to be a rare event in breast cancer and that CEP17 copy number greater than 3.0 in FISH analysis is frequently related to gain or amplification of the centromeric region. Larger studies investigating the genetic profiles of CEP17 polysomic cases are warranted. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- NIHR Biomedical Research Centre
This publication has 25 references indexed in Scilit:
- Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast CancersClinical Cancer Research, 2009
- Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedJournal of Clinical Oncology, 2008
- The genomic profile of HER2‐amplified breast cancers: the influence of ER statusThe Journal of Pathology, 2008
- Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breastThe Journal of Pathology, 2008
- Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell linesLaboratory Investigation, 2008
- Getting it right: designing microarray (and not ‘microawry') comparative genomic hybridization studies for cancer researchLaboratory Investigation, 2007
- Robust smooth segmentation approach for array CGH data analysisBioinformatics, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisationLaboratory Investigation, 2007
- A multiplex PCR predictor for aCGH success of FFPE samplesBritish Journal of Cancer, 2005